Botox for Skin Rejuvenation - Quick Reference Sheet
evipedia.ai
← Back

Botox for Skin Rejuvenation

Created on 08/08/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A purified bacterial protein temporarily switches off the nerve signal to a facial muscle, so the skin it folds lies flatter. Evidence is strong for frown, outer-eye and forehead lines; effects last months, then repeat. Skin-quality claims are weaker. Common problems are temporary; serious harms came almost entirely from counterfeit or mishandled product. Decades-long effects on facial structure are unknown. (Full Review)

Protocol

Standard Upper-Face Dose
64 units
20 units glabella across 5 sites, 24 units crow's feet, 20 units frontalis; full cycle given in one session
Appointment Timing
Morning
Completes the 4-hour upright interval and the 24-hour avoidance of strenuous exercise and sauna within the same day
Male Dosing
1.5–2× female dose
Greater muscle mass; duration often shorter at equivalent dosing
Time to effect
Onset
2–7 days
First softening of dynamic lines
Peak
2–4 weeks
Assessment or touch-up conventionally deferred to the 2-week point
Return to Baseline
3–4 months
Decline from roughly 10 to 12 weeks

Benefits

Contraindications
  • Generalised myasthenia gravis (particularly with bulbar involvement)
  • Lambert-Eaton myasthenic syndrome
  • Amyotrophic lateral sclerosis or any motor neuron disease, and any condition with a forced vital capacity below 80% of predicted
  • Known hypersensitivity to any botulinum toxin preparation or to human serum albumin
  • Active infection, inflammation, or dermatitis at any planned injection site (until resolved)
  • Pregnancy and breastfeeding
  • Prior serious adverse event attributable to distant spread of toxin effect
  • Age outside the approved 18–65 year range
  • Retreatment sooner than 3 months after a previous session
  • Untreated body dysmorphic disorder
    •
Key Interactions
  • Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin, neomycin)
  • Other neuromuscular blocking agents (succinylcholine, rocuronium, vecuronium)
  • Other antibiotics affecting neuromuscular transmission (clindamycin, polymyxin B, colistin, erythromycin, tetracyclines)
  • Anticholinesterase medications (pyridostigmine, neostigmine, donepezil, rivastigmine, galantamine)
  • Centrally acting muscle relaxants (tizanidine, baclofen, cyclobenzaprine, dantrolene)
  • Magnesium salts, quinidine, and calcium channel blockers (verapamil, diltiazem, nifedipine)
  • Prescription anticoagulants and antiplatelet agents (warfarin, apixaban, rivaroxaban, clopidogrel, ticagrelor)
  • Over-the-counter analgesics with antiplatelet activity (aspirin, ibuprofen, naproxen, diclofenac gel)
  • Supplements that impair platelet aggregation (fish oil, vitamin E, Ginkgo biloba, garlic extract, ginger, Curcuma longa extract, nattokinase, high-dose bromelain)
  • Supplements with additive neuromuscular effects (gram-level magnesium, high-dose zinc with anticholinergic botanicals)
  • Supplements proposed to extend duration (zinc citrate combined with phytase)
  • Other aesthetic interventions (fillers, collagen biostimulators, radiofrequency, microfocused ultrasound, lasers, chemical peels, microneedling)

Risk & Side Effects

  • High: Upper eyelid drooping; eyelid and eyebrow malposition; headache; injection-site bruising, pain, and swelling
  • Medium: Eyelid sensory disorder and peri-ocular heaviness; facial asymmetry and loss of natural expression; loss of efficacy from neutralizing antibodies; impaired emotion recognition and blunted affect (conflicted); lower-face and neck complications
  • Low: Distant spread of toxin effect; botulism from counterfeit or mishandled product; long-term muscle atrophy and compensatory recruitment; hypersensitivity reactions; dry eye and ocular surface symptoms
  • Speculative: Accelerated facial fat and bone volume loss over decades; backward transport along nerve fibers to the central nervous system

Monitoring

Marker Target Why
Platelet count 200–350 × 10⁹/L Predicts bruising severity
INR 0.9–1.1 untreated Predicts bruising and hematoma risk
HbA1c < 5.4% Glycated collagen is stiff and rebounds poorly once folding stops
hs-CRP < 0.8 mg/L Systemic inflammation degrades dermal repair and prolongs post-procedural redness
25-hydroxyvitamin D 40–60 ng/mL (100–150 nmol/L) Supports maturation of the outer skin-layer cells and barrier repair
Ferritin 50–150 ng/mL (women), 75–200 ng/mL (men) Low iron stores impair collagen synthesis and slow recovery from micro-injury
TSH 0.5–2.0 mIU/L Thyroid dysfunction produces puffiness around the eyes and skin changes that mimic or mask treatment effects
β-hCG Negative Pregnancy is a contraindication for a discretionary cosmetic procedure
Neutralizing antibody titre Negative Confirms or excludes immune-mediated loss of response
Anti-acetylcholine receptor antibodies Negative Identifies undiagnosed myasthenia gravis before exposure

Cadence: Assessment at 2 weeks after each of the first two cycles, then at 2 weeks after any protocol change; photographic review and skin-quality laboratory panel every 6 to 12 months; antibody testing only if secondary non-response emerges

Qualitative Assessment

  • Onset timing: day softening is first noticed, typically days 2 to 7
  • Duration to return of movement: typically weeks 12 to 16; progressive shortening signals secondary non-response
  • Preserved expressiveness: genuine smiling, surprise, and concern still read on the face, assessed by someone other than the treated person
  • Brow position and heaviness: heavy or tight brow, difficulty fully opening the eyes, change in the visible upper eyelid platform
  • Symmetry at rest and in motion: compared against baseline photographs
  • Skin surface quality: oiliness, pore visibility, and facial redness in standardized photographs
  • Headache and peri-ocular symptoms: frequency and duration in the week after injection, and any dryness, grittiness, or excess tearing
  • Mood and emotional reactivity: any perceived flattening of emotional response or difficulty reading others' expressions
  • Satisfaction over the full cycle: rated at 2 weeks, 8 weeks, and immediately before the next treatment
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.